- Your location: Home
- Research and Campaigns
- Our Research Conference
- Research Conference 2015 - Coeliac disease; prevention and therapeutic advances
- Gluten degradation by ALV003, a novel drug candidate in phase 2B clinical development for coeliac disease
Gluten degradation by ALV003, a novel drug candidate in phase 2B clinical development for coeliac disease
Dr Daniel Adelman
Dr Daniel Adelman is the Chief Medical Officer at Alvine Pharmaceuticals, Inc., a biotechnology company located in the San Francisco Bay Area, USA that is devoted to the development of a pharmaceutical treatment for coeliac disease. Dr Adelman is also a Professor of Medicine at the University of California, San Francisco where he teaches and provides clinical care to patients with immunologically mediated diseases. Dr Adelman has been involved in all stages of therapeutics development as a drug developer. Dr Adelman holds a first degree in biology from the University of California, Berkley and an MD degree from the University of California, Davis. Upon completion of his residency in internal medicine at Cedars Sinai Medical Center in Los Angeles, he did post doctoral fellowship training in clinical immunology and allergy at the University of California, Los Angeles.
Coeliac disease is one of the most common autoimmune diseases and is characterised by chronic, small intestinal immune mediated inflammation, triggered by exposure to dietary gluten in genetically susceptible individuals. The only treatment option currently available is life long adherence to a strict gluten-free diet. However some individuals have difficulties with strict adherence to the diet, can be affected by symptoms reoccurring, have issues with cost and availability of gluten-free foods or feel their lifestyle is restricted. In recent years, there has been growing interest in the pharmaceutical and biotechnology industries to address this unmet medical need and to discover and develop novel, non dietary therapies to help manage this disease. This presentation addresses the unmet medical need and some of the innovative approaches being taken to develop novel therapies for patients with coeliac disease who, despite following a gluten-free diet, continue to experience disease related symptoms and gut inflammation.